by Black Brittain
(Reuters) – Indian generic drugmaker Lupin Pharmaceuticals Inc has agreed to pay $150 million to settle claims brought by a group of grocery stores, drug stores and other direct buyers of the diabetes drug Glumetza for its role in an alleged “pay-for-delay” scheme that supposedly raised the drug’s price by nearly 800%, according to a filing in San Francisco federal court.
Lupin’s settlement filed with the court Monday, comes shortly after Glumetza’s maker, Bausch Health Cos Inc agreed to pay $300 million to settle the purchasers’ antitrust claims. The purchasers had accused the Laval, Canada-based company and Lake Forest, Illinois-based Assertio Therapeutics Inc of paying Lupin to delay its generic version of the Type 2 diabetes drug in exchange for agreeing not to compete with the generic.
A jury trial before U.S. District Judge William Alsup was set to begin in October.
Lupin and its attorneys Jay Lefkowitz and Devora Allon of Kirkland & Ellis didn’t immediately respond to a request for comment, nor did the purchasers’ attorneys Lauren Barnes and Shana Scarlett of Hagens Berman Sobol Shapiro, Joseph Vanek of Sperling & Slater, and Steve Shadowen of Hilliard & Shadowen.
Article available at https://www.reuters.com/legal/litigation/lupin-agrees-pay-150-mln-settle-glumetza-antitrust-claims-2021-09-21/